Cyclin-dependent kinase inhibitors
AssigneeSpv Therapeutics Inc.
InventorsSubba R. Katamreddy, Yousry Sayed, Naresh Ramireddy
Life of this patent
Estimating the term…
Abstract
Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.
Claims14
A compound or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (I) or (II):
- wherein A is H, F, Me, or CON(Me)2;
- X and Y are independently C—H, N, or C—F;
- is
- or CN;
- where L is none, CH2, CO, NH, O, or S;
- R is
- where Rx is H or Me;
- and
- R1 is
- where R3 is H, Me, CH2CH2OH, isopropyl, isobutyl, or bicyclo[1.1.1]pentane;
- R4 is H, Me, OMe, CF3, or CHF2;
- R5 is H or Me;
- R6 is Me, CH2CH2OH, isopropyl, isobutyl, or bicyclo[1.1.1]pentane;
- X is C—H, N, or C—F;
- Z is C—H or C—F;
- Y1 is H, NH2, F, Me, OMe, CF3, or CHF2;
- Q is O or S;
- n is 1, 2, or 3;
- and
- R2 is:
- where T is O, NH, NMe, N-isopropyl, or N-isobutyl.
A compound selected from compounds A14, A16, A17, A30, A31, A37, A39-A40, A44-A85, and A88-A93 or pharmaceutically acceptable salts thereof:
A compound selected from compounds A14, A16, A17, A30, A31, A37, A40, A44, A45, A47-A56, A59-A63, A65-A85, and A88-A93 or pharmaceutically acceptable salts thereof:
Dependencies are inferred from the claim text.